Surface projection of murine major histocompatibility determinants induced by hydrostatic pressure and cytokines

Pathobiology

Volumn 64, Issue 3, 1996, Pages 142-149

  Eisenthal, Avi ^a   Matsaev, Andre ^b   Gelfand, Anna ^a   Kahn, Perry ^a   Lifschitz Mercer, Beatriz ^a   Skornick, Yehuda ^a   Shinitzky, Meir ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cytokines; Major histocompatibility complex; Pressure and cross linking; Tumor vaccine

Indexed keywords

CYCLOHEXIMIDE; CYTOKINE; GAMMA INTERFERON; H2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; FEMALE; HYDROSTATIC PRESSURE; IMMUNOGENICITY; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN SYNTHESIS; PROTEIN TRANSPORT;

ANIMALIA; MURINAE;

EID: 0029779242     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000164028     Document Type: Article

References (26)

1. Rao A, Allard WJ, Hogan PG, Rosenson RS, Cantor H: AllorcactiveT-cell clones: Ly phenotype predicts both function and specificity for MHC products, Immunogenetics 1983:17:147.
2. Doherty P, Knowles B, Wettstcin P: Immunological surveillance of tumors in the context of major histocompatibility complex restriction of T cell function, Adv Cancer Res 1984:42:1.
3. Kenneth LR, Rothslein LE, Gamble SR, Bcna-ccrraf B: Reassociation with beta-2 microglobulin is necessary for Kb class I major histocompatibility complex binding to exogenous peptides, Proe Natl Acad Sci 1990:87:7517.
4. Schumacher NM, DcBruijn MEH, Vemie N, Kasl WM, Melief JM, Nccfjcs J, Plocgh HL: Peptide selection by MHC class I molecules, Nature 1991:350:703.
5. Doyle A, Martin WJ, Fuña K, Gazdar A, Carney D, Martin SE, Linnoila I, Cuttitta F, Mul-shine J, Bunn P, Minna J: Markedly decreased expression of class 1 histocompatibility antigens, protein, and mRNA in human small-cell lung cancer, J Exp Med 1985; 161:1135.
6. Restfio NP, Kawakami Y, Marineóla F, Sha-mamian P, Taggarsc A, Esquivel F, Rosenberg SA: Molecular mechanisms used by tumors to escape immune recognition: Immunotherapy and cell biology of major histocompatibility complex class, J Immunol 1993:14:182.
7. h gene transfection on the metastatic ability of B16 melanoma cells, Int J Cancer 1991:48: 270.
8. Weber JS, Jay G, Tanaka K, Rosenberg SA: Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after class 1 gene transfection, J Exp Med 1987:166:1716.
9. Weber JS, Rosenberg SA: Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro, Cancer Res 1988:48:5818.
10. Ramakrishna V, Shinitzky M: Potentiation of delayed-tvpc hypersensitivity response to syngeneic tumors in mice prevaccinated with cells modified by hydrostatic pressure and cross-linking, Cancer Immunol Immunothcr 1991; 31:1-8.
11. Ramakrishna V, Eiscnthal A, Skornick Y, Shinitzky M: Increased projection of MHC and tumor antigens in murine B16-BL6 melanoma induced by hydrostatic pressure and chemical crosslinking, Cancer Immunol Immunothcr 1993;36:293.
12. Eiscnthal A, Ramakrishna V, Skornick Y, Shinitzky M: Induction of ccll-mcdiated immunity against BI6-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical cross-linking, Cancer Immunol 1993:36:300.
13. Gorelick E, Peppoloni S, Overton R, Herber-man R: Increase in H-2 antigen expression and immunogcnicity of BL6 melanoma cells treated with N-methy-N'-nitro-nitrosoguanid-inc, Cancer Res 1985:45:5341.
14. Sachs DH, Cone JL: A murine B-cell ailoanti-gen determined by gene(s) linked to the major histocompatibility complex, J Exp Med 1973: 138:1289.
15. Fisenthal A, Shiloni E, Rosenberg SA: Characterization of IL-2-induced murine cells which exhibit ADCC activity, Cell Immunol 1988; 115:257.
16. Gehan EA: Generalized Wilcoxon test for comparing arbitrarily single censored samples, Bio-metrica 1965:52:203.
17. Gracomini P, Aguzzi A, Pcstka S, Fisher PB, Fcrronc S: Modulation by recombinant DNA leucocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA-and tumor associated antigens by human melanoma cells, J Immunol 1984:133:1649.
18. Greiner JW, Horan Hand P, Noguchi P, Pestka S, Seldom J: Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-intcrferon treatment, Cancer Res 1984:44:3208.
19. Pfizcnmeir K, Scheurich P, Schultcr C, Kronkc M: Tumor necrosis factor enhances HLA-A, B, C and DR gene expression in human tumor cells, J Immunol 1987:138:975.
20. Pujol-Barrel R, Todd I, Doshi M, Bottazzo GF, Sutton R, Gray D, Adolf GR, Feldman M: HLA class II induction in human islet cells by inlcrfcron-gamma plus tumor necrosis factor of lymphotoxin, Nature 1987:326:304.
21. Greiner JW, Fisher PB, Pestka S, Schlom J: Differential effects of recombinant human leukocyte interferons on cell surface antigen expression, Cancer Res 1986:46:4984.
22. Shinitzky M: Membrane fluidity in malignancy - Adversative and recuperative, Biochim Bio-physActa 1984:738:251-261.
23. Eisenbach L, Kushtai G, Plotkin D, Feldman M: MHC genes and oncogenes control the metastatic phenotype of tumor cells, Cancer Rev 1986:5:1.
24. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffcc E, Pardoll D, Levitsky H: Role of bone marrow-derived eells in presenting MHC class l-rcstricted tumor antigens, Science 1994:264: 96.
25. Srivastava PK, Udono H, Blachcre NE, Li Z: Heat shock proteins transfer peptides during antigen processing and CTL priming, J lmmuno-genetics 1994:39:93.
26. Rosenberg SA, Spiess P, Lafrcnicre R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes, Science 1986:233:1318.